RenovaCare, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RCAR research report →
Price Chart
About the company
RenovaCare, Inc. , a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area.
- CEO
- Harmel Singh Rayat
- IPO
- 1996
- Employees
- 1
- HQ
- Scottsdale, AZ, US
Get TickerSpark's AI analysis on RCAR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.73K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -94.75%
- ROIC
- -227.54%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-10,968+50.2%
- Op Income
- $-5,409,416
- Net Income
- $-4,465,306+53.2%
- EPS
- $-0.05+53.5%
- OCF Growth
- +3.4%
- FCF Growth
- +4.2%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 5.62
- RSI (14)
- 53
- Avg Volume
- 27
No earnings-call transcripts are available for RCAR yet.
- Free Float
- 25.7%
- Shares Outstanding
- 87.35M
- Float Shares
- 22.46M
of shares held by institutions
1 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 1 ETFs
Biggest fund positions in RCAR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 16, 16 | Kirkland Kenneth | other | 50,000 |
| Mar 16, 15 | Bold Thomas | other | 60,000 |
| Mar 16, 16 | Rosen Rhonda Beth | other | 20,000 |
| Mar 16, 16 | SIERCHIO JOSEPH | other | 50,000 |
| Feb 2, 16 | RAYAT HARMEL S | buy | 2,173,913 |
| Feb 2, 16 | RAYAT HARMEL S | other | 2,173,913 |
| Dec 31, 15 | RAYAT HARMEL S | other | 3,800,000 |
| Dec 31, 15 | RAYAT HARMEL S | other | 3,000,000 |
| Dec 31, 15 | RAYAT HARMEL S | other | 12,000 |
| Dec 31, 15 | RAYAT HARMEL S | other | 800,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RCAR coverage
Recent articles, reports, and earnings notes.
No research on RCAR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RCAR report →Contrasting Biofrontera (NASDAQ:BFRI) & RenovaCare (OTCMKTS:RCAR)
defenseworld.net · Feb 19
RenovaCare Inc. Provides Notice of Proposed Derivative Settlement to All Record Holders and Beneficial Owners of RenovaCare, Inc.
businesswire.com · Feb 12
Hagens Berman Sobol Shapiro LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of RenovaCare Securities - RCAR
globenewswire.com · Jan 17
RenovaCare Announces Termination of StemCell Systems R&D Agreement
globenewswire.com · May 3
SHAREHOLDER ALERT: Rigrodsky Law, P.A. is Investigating RenovaCare, Inc.
newsfilecorp.com · Apr 14
RenovaCare Announces Management Changes
globenewswire.com · Mar 24
RenovaCare Provides Clinical and Corporate Update
globenewswire.com · Mar 9
RM LAW Announces Investigation of RenovaCare, Inc.
prnewswire.com · Feb 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.